Print Page  Close Window

SEC Filings

S-1
VITAE PHARMACEUTICALS, INC filed this Form S-1 on 08/12/2014
Entire Document
 

Table of Contents

The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

Subject To Completion, Dated August 12, 2014

Preliminary Prospectus


GRAPHIC

                 Shares
Common Stock
$      .      per share


This is the initial public offering of Vitae Pharmaceuticals, Inc. We are offering                  shares of common stock. Prior to this offering, there has been no public market for our common stock. We estimate that the initial public offering price will be between $            and $            per share.

We have applied to list our common stock on The NASDAQ Global Market under the symbol "VTAE."

We are an "emerging growth company" under the Jumpstart Our Business Startups Act of 2012 and applicable Securities and Exchange Commission rules, and, as such, have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings. See "Prospectus Summary—Emerging Growth Company Status."


Investing in our common stock involves a high degree of risk. See "Risk Factors" beginning on page 11.


 
  Per Share
  Total
 

Initial public offering price

  $     $    

Underwriting discounts and commissions(1)

  $     $    

Proceeds, before expenses, to us

  $     $    

(1)
See "Underwriting" beginning on page 156 for additional information regarding underwriting compensation.

We have granted the underwriters a 30-day option to purchase up to                        additional shares of common stock on the same terms and conditions set forth above.

The underwriters expect to deliver the shares to purchasers on                        , 2014.


Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.


Stifel

  BMO Capital Markets

JMP Securities

  Wedbush PacGrow Life Sciences

   

The date of this prospectus is                        , 2014.